Johnson & Johnson (JNJ) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong Q3 2025 beat with raised guidance, multiple near-term FDA approvals boosting revenue prospects, strategic M&A enhancing growth, robust free cash flow, and positive technical momentum just below the upper Bollinger band support a favorable near-term price appreciation setup.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Strong free cashflow ⢠Rising net debt JNJ's margins, cash generation and lower implied multiples strengthen the investment case, but rising net debt, falling cash/working capital and increased intangibles raise monitoring risks.
Price Behavior
Key Price Behavior Insights: ⢠Upward momentum ⢠Support cluster ⢠Resistance cap Support Level: $205â$207 Resistance Level: $214 Over the last month JNJ has trended upward from a mid-December dip near $199.96 to about $209.72 by 2026-01-12, establishing support around $205â$207 but facing resistance near $214 amid volatile short-term swings.
Sentiment & News
Key News Insights: ⢠Kenvue spin-off ⢠Pipeline momentum ⢠Institutional buying Johnson & Johnson completed its Kenvue spin-off, is refocusing on high-value immunology/MedTech assets with promising pipeline catalysts, and has seen renewed institutional buying supporting a cautiously optimistic outlook.
AI Summary
Post-spin J&J is now a higherâmargin Innovative Medicine + MedTech growth platformâso investment returns will be driven more by pipeline readouts, M&A execution and litigation timing than by legacy consumer cash flows, making upside from TREMFYA/DARZALEX and OTTAVA contingent on successful trials/commercial execution while rising leverage and talc settlement risk could materially compress equity value.
Description
Johnson & Johnson develops, manufactures and sells healthcare products worldwide through three principal businesses: Consumer Health, Pharmaceuticals and MedTech. Its Consumer Health unit offers household personal-care and over-the-counter medicines, the Pharmaceuticals division markets prescription therapies across immunology, infectious disease, CNS, oncology, cardiovascular and metabolic indications, and the MedTech business supplies devices for cardiovascular, neurovascular, orthopaedic, surgical and vision care. The company distributes to retailers, wholesalers, hospitals and healthcare professionals and is headquartered in New Brunswick, New Jersey; it was founded in 1886.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 17 | Nov 24 | JNJ | Johnson & Johnson | Strong Q3 2025 beat with raised guidance, multiple near-term FDA approvals boosting revenue prospects, strategic M&A enhancing growth, robust free cash flow, and positive technical momentum just below the upper Bollinger band support a favorable near-term price appreciation setup. | Closed | +3.2% |